The New York Times | Our Drug Supply Is Sick. How Can We Fix It?
The American health care system is built on the idea that a pill is a pill.
In a New York Times article titled "Our Drug Supply Is Sick. How Can We Fix It?" Farah Stockman discusses issues in the American generic drug supply chain, focusing on the closure of the Mylan plant in Morgantown, West Virginia. The generic drug industry, built on the concept that all pills are equal, faces challenges such as price competition, chronic shortages, illegal practices, and production moving overseas. The shift to low-wage countries, combined with the industry's lack of transparency, raises concerns about drug quality. The closure of the Mylan plant, once known for high-quality manufacturing, highlights the broader problems in the generic drug supply. The article suggests that the free market is not working for generic drugs and proposes the implementation of a quality rating system to incentivize companies to invest in quality. Nonprofits like Civica Rx are also explored as potential solutions to address drug shortages and quality issues in the generic drug supply chain. The piece recognizes Valisure as a leader attempting to address these issues and highlights the opportunities for change through action by large health systems.
View the full article via The New York Times.
